Therapy Final Exam Review – Complete
Question Bank with Answers.
45-year-old African American woman who was a
previous smoker has a BMI of 32 kg/m2. She is currently
on a 1-week taper of Prednisone for an asthma flair.
She is also taking Lisinopril 20 mg for HTN. Which of the
following is associated with the most INCREASED risk for
her developing osteoporosis in this patient?
a. AA ethnicity
b. Past smoker
c. Present use of steroids
d. Female gender
e. BMI > 30 kg/m2
d. Female gender
72 y/o woman with a history of vertebral compression fracture and a DEXA T score of -2.7 in the
left hip. What is the best initial therapy for this patient?
A. Fosamax [Alendronate] 70 mg weekly
B. Calcitonin [1] spray to alternating nares qd
C. Prempro [estrogen / progestin] 0.625/2.5 mg [1] qd
D. Prolia [Denosumab] 60 mg SQ every 6 months
A. Fosamax [Alendronate] 70 mg weekly
75 y/o woman with newly diagnosed osteoporosis, being
discharged after total hip replacement due to right hip
fracture. She has never been medication for
osteoporosis. PMH is significant for severe GERD, DVT [20
years ago], atrial fibrillation and family history of breast
cancer. Which therapy may offer the MOST benefit in
this patient?
A. Prolia [Denosumab] 60 mg SQ every 6 months
B. Calcitonin [1] spray to alternative nares qd
C. Evista [Raloxifene] 60 mg daily
,D. Forteo [Teriparatide] 20 mcg SC daily
E. Reclast [Zoledronic acid] 5 mg IV every 12 monthS
A. Prolia [Denosumab] 60 mg SQ every 6 months
68 y/o post menopausal woman with a history of T2DM,
CAD, dyslipidemia, GERD, OA of knees, stage 3 CKD.
Recent EGD was unremarkable. DEXA scan showed T
score of -3 of the left hip. Which of the following
precludes the used of a bisphosphonate?
A. Age
B. Renal disease
C. GERD
D. OA
E. DM
B. Renal disease
53 y/o woman with history of esophageal stricture—
recently treated successfully with dilatation—from
longstanding GERD, and vasomotor symptoms of
menopause. A recent DEXA showed a T score of -2.5 of
the LS spine and -2.6 in the left hip. Which therapy is
MOST appropriate?
A. Prolia [Denosumab] 60 mg SQ every 6 months
B. Evista [Raloxifene] 60 mg po daily
C. Actonel [Risedronate] 35 mg po weekly
D. Boniva [Ibandronate] 150 mg po monthly
E. Calcitonin 200 units alternate nares qd
A. Prolia [Denosumab] 60 mg SQ every 6 months
38 y/o woman who is at a health fair. She asks what she can do to
maintain her bone health. Her mum had severe osteoporosis with vertebral
fractures, spinal kyphosis, hip fracture and limited mobility. Your patient is
64 inches tall and weighs 115 pounds. She is postmenopausal. Her meds
include OCP and a multivitamin daily; her DEXA scan shows a T score of
1.3 and a Z score of -.8. which exercise regimen is going to be most helpful
to improve her bone health?
A. Stair climbing
B. Cycling
, C. Water aerobics
D. Yoga
E. Spin class
F. Running
G. A, D and F
H. A and F
G. A, D and F
68 y/o man with several risk factors for osteoporosis—
cigarette smoking, drinking 3-5 alcoholic drinks/day, low
body weight and sedentary lifestyle. Labs reveal a 25
Vitamin D level of 18 mcg. Of the following, what will you
recommend?
A. Increase dietary intake of milk, eggs and catfish
B. Increase sun exposure
C. Calcium citrate with Vitamin D [200/200 IU] BID
D. Vitamin D2 50,000 IU daily for 6-12 months
E. Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then
5,000 IU thereafter
E. Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then 5,000 IU thereafter
Which agent [s] has/have a low likelihood of causing CV
adverse effects in a patient with BPH who is also taken meds
for HTN?
1. Alfuzosin [Uroxatrol]
2. Tamulosin [Flomax]
3. Finasteride [Proscar]
A. 1 only
B. 2 only
C. 3 only
D. 1 and 3
E. 2 and 3
F. 1, 2 and 3
E. 2 and 3
Stimulation of muscarinic cholinergic receptors in the
bladder muscle may be responsible for:
A. Functional incontinence